Cenerimod

CAS : 1262414-04-9

Ref. 3D-MAC41404

Informations sur le produit

• Nom: Cenerimod
• Synonymes: T14924, 1,2-Propanediol, 3-[4-[5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-, (2S)-, (S)-3-(4-(5-(2-CYCLOPENTYL-6-METHOXYPYRIDIN-4-YL)-1,2,4-OXADIAZOL-3-YL)-2-ETHYL-6-METHYLPHENOXY)PROPANE-1,2-DIOL, ACT-334441

Description

Cenerimod is a small molecule that inhibits the activity of TNF-α and IL-1β, which are pro-inflammatory cytokines. It has been shown to reduce clinical response and disease activity in patients with inflammatory bowel disease (IBD) and Crohn’s disease. Cenerimod is administered orally, and the pharmacokinetic properties have been characterized in healthy volunteers and patients with hepatic impairment or autoimmune diseases. The terminal half-life of cenerimod ranges from 3 to 5 hours, depending on the condition of the patient. The drug undergoes extensive first-pass metabolism, primarily by CYP3A4, CYP2C8, CYP2C9, CYP2C19, and UGT1A6 enzymes. Cenerimod is eliminated primarily through biliary excretion as metabolites; it does not bind to plasma proteins.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 453.53 g/mol
• Formule: C₂₅H₃₁N₃O₅
• Degré de pureté: Min. 95%